Health and Healthcare
Bristol-Myers Re-Offers No New Offer for ImClone (IMCL, BMY)
Published:
Bristol-Myers Squibb (NYSE: BMY) has sent a letter to Imclone Systems (NASDAQ: IMCL) in response to yesterday’s rejection of its buyout offer. It said it is disappointed that the $60.00 bid was passed up for a highly conditional higher offer subject to due diligence. Bristol’s offer is not subject to due diligence. Bristol-Myers also said it will not make any alterations to its exclusive marketing rights for ERBITUX and the related compounds (including IMC-11F8).
As the letter states….."Notwithstanding ImClone’s receipt of ahighly conditional preliminary proposal from another party, we continueto look forward to engaging directly with ImClone and its financial andlegal advisors to discuss the merits of our all-cash offer, which isnot subject to due diligence or financing, to acquire the approximately83% of ImClone that we do not already own."
In short, Bristol-Myers is trying to start flexing its muscles now thatImClone and Carl Icahn have started showing face cards. ImClone is down1.4% at $66.95 today. Technically, this is no more than step-3 of along series of steps in an Icahn merger game.
Jon C. Ogg
September 11, 2008
100 Million Americans Are Missing This Crucial Retirement Tool
The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.
Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.
A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.
Click here to learn how to get a quote in just a few minutes.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
